Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy

{
"level_sex_clusion_I": [
{
"concept": {
"vocab": "MeSH",
"vocabURI": "D005260"
},
"value": "Female"
},
{
"concept": {
"vocab": "MeSH",
"vocabURI": "D008297"
},
"value": "Male"
}
],
"level_age_clusion_I": [
{
"concept": {
"vocab": "MeSH",
"vocabURI": "D055815"
},
"value": "Young Adult (19 to 24 years)"
},
{
"concept": {
"vocab": "MeSH",
"vocabURI": "D000328"
},
"value": "Adult (25 to 44 years)"
},
{
"concept": {
"vocab": "MeSH",
"vocabURI": "D008875"
},
"value": "Middle Aged (45 to 64 years)"
},
{
"concept": {
"vocab": "MeSH",
"vocabURI": "D000368"
},
"value": "Aged (65 to 79 years)"
},
{
"concept": {
"vocab": "MeSH",
"vocabURI": "D000369"
},
"value": "Aged, 80 and over (80 years and more)"
}
],
"level_type_clusion_I": "Patients population",
"level_type_clusion_other": "",
"clusion_I": "Aged 18 years and over; - Cardiomyopathy defined by an ultrasound thickness of the left ventricle greater than or equal to13 mm if familial form, or greater than or equal to 15 mm if sporadic form; - Patients with a signed consent authorising the specific blood test for genetic sequencing to look for an abnormal TTR gene. ",
"clusion_E": "Significant AS (less than or equal to 1cm2); - Patients with a cardiomyopathy diagnosis (sarcomeric HCM, Fabry disease, etc.) or related already diagnosed.Patients included in the REMY registry (Hypertrophic Cardiomyopathy Registry) may also be included in the amyloid-STUDY. Inclusion criteria are very similar. Some additional data will need to be completed on the page corresponding to the registry."
}